// App-Quantinova.ai

: Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS)

Researchers

Presenter

  • Tapan M. Kadia

Principal Investigators

  • Christopher Benton

  • Harry P. Erba

  • Mitul Gandhi

  • Moshe Y. Levy

  • Mary-Elizabeth M. Percival

  • Matthew Ulrickson

  • Habte Yimer

  • Min Yu

  • Zi Chen

  • Jing Wang

  • Mingyu Li

  • Mohammad Ahmad

  • Dajun Yang

  • Yifan Zhai

Medical Centers

  • Texas Oncology-NorthEast Texas, Tyler, TX

  • Leukemia Program, Duke University Medical Center, Durham, NC

  • Fred Hutchinson Cancer Center, Seattle, WA

  • Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX

  • Virginia Cancer Specialists, Gainesville, VA

  • Banner MD Anderson Cancer Center, Gilbert, AZ

  • Rocky Mountain Cancer Center, Englewood, CO

Locations

  • United States

  • China

Companies

  • Ascentage Pharma Gro

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic myelomonocytic leukemia

  • Alpha-thalassemia myelodysplasia syndrome

  • Acute myelocytic leukemia

Biomarkers

  • Patched 1

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Vidaza

Outcome

  • N/A

Study Design

  • Safety

  • Multicenteric

  • Tolerability

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved